8 completed, 1 not yet recruiting, 1 terminated. 4 Phase 2, 4 Phase 3, 1 Phase 1, 1 Phase 4.
By phase and status
Follow Blastomycosis: new trials by email Literature Review of Blastomycosis trials Research Report on Blastomycosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi Oteseconazole - Coccidioidomycosis, Blastomycosis Phase 2 Not yet recruiting University of Minnesota 30 2026-12-01 2026-09-04 A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica. Sporotrichosis, Chromomycosis Completed Caja Costarricense de Seguro Social 95 2023-12-11 2024-07-29 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections Phase 2 / Phase 3 Completed University of Alabama at Birmingham 88 2018-09-17 2023-07-07 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis Phase 3 Completed Scynexis, Inc. 233 2017-04-01 2024-11-20 Amphotericin-B and Voriconazole for Pulmonary Blastomycosis amphotericin-B, voriconazole - Blastomycosis Phase 4 Terminated University of Manitoba 2 2015-06-01 2020-09-29 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection ITCZ Oral Solution, ITCZ-IV - Mycoses, Candidiasis Phase 3 Completed Janssen Pharmaceutical K.K. 55 2008-01-01 2013-07-25 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection Blastomycosis Completed National Cancer Institute (NCI) 400 1998-07-29 2017-07-02 Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis fluconazole - Histoplasmosis, Sporotrichosis Phase 2 Completed National Center for Research Resources (NCRR) 78 1991-09-01 2006-06-09 Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis itraconazole - Histoplasmosis, Sporotrichosis Phase 1 / Phase 2 Completed National Center for Research Resources (NCRR) 7 1985-03-01 2006-06-09 A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis Itraconazole, Amphotericin B - HIV Infections, Histoplasmosis Phase 3 Completed Janssen, LP 60 2005-06-24
Narrower conditions Histoplasmosis (7) · Coccidioidomycosis (4) · Mycoses (3) · Sporotrichosis (3) · Communicable Diseases (2) · Immune System Diseases (2) · Rare Diseases (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Actinomycosis (1) · Aspergillosis (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bacterial Infections and Mycoses (1) · Candidiasis (1)
Broader conditions Dermatomycoses (10) · Infections (10) · Lung Diseases (10) · Lung Diseases, Fungal (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (10) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Bacterial Infections and Mycoses (9) · Skin Diseases, Infectious (9) · Mycoses (7) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Genital Diseases (2)
Interventions Itraconazole (3) · Amphotericin B (2) · Fluconazole (1) · Voriconazole (1) · ibrexafungerp (1)
Sponsors National Center for Research Resources (NCRR) (2) · Caja Costarricense de Seguro Social (1) · Janssen Pharmaceutical K.K. (1) · Janssen, LP (1) · National Cancer Institute (NCI) (1) · Scynexis, Inc. (1) · University of Alabama at Birmingham (1) · University of Manitoba (1) · University of Minnesota (1)
Countries United States (5) · Austria (1) · Canada (1) · Costa Rica (1) · Germany (1) · Japan (1) · Netherlands (1) · Pakistan (1) · Panama (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Top investigators William Dismukes (2) · Andrej Spec, MD (1) · Daniel E Barquero Orias, MD (1) · George R Thompson, MD (1) · Matthew Pullen, MD (1) · Peter G Pappas, MD (1) · Robert E. Ariano, Pharm.D. (1)
Results publications PMID 32457106 , PMID 38440302
NIH funding 2017 (1)